The toll-like receptor 9 ligand CPG-C attenuates acute inflammatory cardiac dysfunction

Shock

Volumn 36, Issue 5, 2011, Pages 478-483

  Mathur, Sumeet ^a   Walley, Keith R ^a   Boyd, John H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

cardiac contractility; cytokines; ejection fraction; inflammation; ischemia reperfusion; LPS; Toll like receptors

Indexed keywords

CALGRANULIN A; CALGRANULIN B; CPG OLIGODEOXYNUCLEOTIDE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; PROTEIN; TNIP1 PROTEIN; TOLL LIKE RECEPTOR 9; TRIM30 PROTEIN; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDITIS; CELL STIMULATION; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FOLLOW UP; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSTHORACIC ECHOCARDIOGRAPHY; UPREGULATION;

ANIMALS; ECHOCARDIOGRAPHY; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTOR 9;

EID: 80054925307     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31822d6442     Document Type: Article

References (35)

1. Brown MA, Jones WK: NF-kappaB action in sepsis: the innate immune system and the heart. Front Biosci 9:1201-1217, 2004. (Pubitemid 39060836)
2. Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR: Toll-like receptor stimulation in cardiomyocytes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res 72(3):384-393, 2006. (Pubitemid 44665856)
3. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR: S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res 102(10):1239-1246, 2008.
4. Frantz S, Tillmanns J, Kuhlencordt PJ, Schmidt I, Adamek A, Dienesch C, Thum T, Gerondakis S, Ertl G, Bauersachs J: Tissue-specific effects of the nuclear factor kappaB subunit p50 on myocardial ischemia-reperfusion injury. Am J Pathol 171(2):507-512, 2007. (Pubitemid 47344683)
5. Klaschik S, Tross D, Klinman DM: Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo. J Leukoc Biol 85(5):788-795, 2009.
6. Tross D, Petrenko L, Klaschik S, Zhu Q, Klinman DM: Global changes in gene expression and synergistic interactions induced by TLR9 and TLR3. Mol Immunol 46(13):2557-2564, 2009.
7. Michael LH, Entman ML, Hartley CJ, Youker KA, Zhu J, Hall SR, Hawkins HK, Berens K, Ballantyne CM: Myocardial ischemia and reperfusion: a murine model. Am J Physiol 269(6 Pt 2):H2147YH2154, 1995. (Pubitemid 26023233)
8. Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, Krieg AM, Cameron DW: CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. Aids 19(14):1473-1479, 2005. (Pubitemid 41400692)
9. Dalpke AH, Lehner MD, Hartung T, Heeg K: Differential effects of CpG-DNA in Toll-like receptor-2/-4/-9 tolerance and cross-tolerance. Immunology 116(2): 203-212, 2005. (Pubitemid 41368662)
10. McCluskie MJ, Krieg AM: Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol 311: 155-178, 2006. (Pubitemid 47413198)
11. Noll BO, McCluskie MJ, Sniatala T, Lohner A, Yuill S, Krieg AM, Schetter C, Davis HL, Uhlmann E: Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration. Biochem Pharmacol 69(6):981-991, 2005. (Pubitemid 40312715)
12. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, et al.: Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 34(1):251-262, 2004. (Pubitemid 38111541)
13. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA: Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 104(3):271-280, 1999.
14. Birks EJ, Felkin LE, Banner NR, Khaghani A, Barton PJ, Yacoub MH: Increased Toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. J Heart Lung Transplant 23(2):228-235, 2004. (Pubitemid 38175301)
15. Akira S: Toll-like receptors: lessons from knockout mice. Biochem Soc Trans 28(5):551-556, 2000.
16. Akira S, Takeda K, Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2(8):675-680, 2001. (Pubitemid 32747155)
17. Knuefermann P, Sakata Y, Baker JS, Huang CH, Sekiguchi K, Hardarson HS, Takeuchi O, Akira S, Vallejo JG: Toll-like receptor 2 mediates Staphylococcus aureusYinduced myocardial dysfunction and cytokine production in the heart. Circulation 110(24):3693-3698, 2004. (Pubitemid 39665259)
18. Takeda K, Akira S: Toll-like receptors in innate immunity. Int Immunol 17(1): 1-14, 2005.
19. Kawai T, Akira S: TLR signaling. Semin Immunol 19(1):24-32, 2007. (Pubitemid 46498752)
20. Bianchi ME: DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81(1):1-5, 2007. (Pubitemid 46028489)
21. Kariko K, Weissman D, Welsh FA: Inhibition of Toll-like receptor and cytokine signalingYa unifying theme in ischemic tolerance. J Cereb Blood Flow Metab 24(11):1288-1304, 2004. (Pubitemid 39482492)
22. Dybdahl B, Slordahl SA, Waage A, Kierulf P, Espevik T, Sundan A: Myocardial ischaemia and the inflammatory response: release of heat shock protein 70 after myocardial infarction. Heart 91(3):299-304, 2005. (Pubitemid 40299205)
23. Zou N, Ao L, Cleveland JC Jr, Yang X, Su X, Cai GY, Banerjee A, Fullerton DA, Meng X: Critical role of extracellular heat shock cognate protein 70 in the myocardial inflammatory response and cardiac dysfunction after global ischemiareperfusion. Am J Physiol Heart Circ Physiol 294(6):H2805YH2813, 2008.
24. de Jong PR, Schadenberg AW, Jansen NJ, Prakken BJ: HSP70 and cardiac surgery: molecular chaperone and inflammatory regulator with compartmentalized effects. Cell Stress Chaperones 14(2):117-131, 2009.
25. Mehra VC, Ramgolam VS, Bender JR: Cytokines and cardiovascular disease. J Leukoc Biol 78(4):805-818, 2005. (Pubitemid 41384397)
26. Frantz S, Hu K, Bayer B, Gerondakis S, Strotmann J, Adamek A, Ertl G, Bauersachs J: Absence of NF-kappaB subunit p50 improves heart failure after myocardial infarction. FASEB J 20(11):1918-1920, 2006.
27. Chong AJ, Shimamoto A, Hampton CR, Takayama H, Spring DJ, Rothnie CL, Yada M, Pohlman TH, Verrier ED: Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg 128(2):170-179, 2004. (Pubitemid 38969797)
28. Shimamoto A, Pohlman TH, Shomura S, Tarukawa T, Takao M, Shimpo H: Toll-like receptor 4 mediates lung ischemia-reperfusion injury. Ann Thorac Surg 82(6):2017-2023, 2006.
29. Tillmanns J, Carlsen H, Blomhoff R, Valen G, Calvillo L, Ertl G, Bauersachs J, Frantz S: Caught in the act: in vivo molecular imaging of the transcription factor NF-kappaB after myocardial infarction. Biochem Biophys Res Commun 342(3):773-774, 2006. (Pubitemid 43320465)
30. Knuefermann P, Schwederski M, Velten M, Krings P, Ehrentraut H, Rudiger M, Boehm O, Fink K, Dreiner U, Grohe C, et al.: Bacterial DNA induces myocardial inflammation and reduces cardiomyocyte contractility: role of Tolllike receptor 9. Cardiovasc Res 78(1):26-35, 2008. (Pubitemid 351430962)
31. Wang J, Hu Y, Deng WW, Sun B: Negative regulation of Toll-like receptor signaling pathway. Microbes Infect 11(3):321-327, 2009.
32. Ghosh S, Hayden MS: New regulators of NF-kappaB in inflammation. Nat Rev Immunol 8(11):837-848, 2008.
33. Stevens SL, Ciesielski TM, Marsh BJ, Yang T, Homen DS, Boule JL, Lessov NS, Simon RP, Stenzel-Poore MP: Toll-like receptor 9: a new target of ischemic preconditioning in the brain. J Cereb Blood Flow Metab 28(5):1040-1047, 2008. (Pubitemid 351589642)
34. Vasileiou I, Kostopanagiotou G, Katsargyris A, Klonaris C, Perrea D, Theocharis S: Toll-like receptors: a novel target for therapeutic intervention in intestinal and hepatic ischemia-reperfusion injury? Expert Opin Ther Targets 14(8):839-853, 2010.
35. Marsh BJ, Stevens SL, Hunter B, Stenzel-Poore MP: Inflammation and the emerging role of the Toll-like receptor system in acute brain ischemia. Stroke 40(Suppl 3):S34YS37, 2009.